Anzeige
Mehr »
Login
Sonntag, 27.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Forge Resources (WKN: A40AT2) durchbricht die 1 CAD-Marke - 300?% Rallye entfacht neue Dynamik!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
333 Leser
Artikel bewerten:
(1)

DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator's Chief Operating Officer

Finanznachrichten News

CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator in China ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Officer Prof. Chaim Lotan to lead the effort at DiNovA Israel to promote innovative medtech innovations.

Mr. Yaniv Kirma has over 20 years of experience in leading diversified cross-organizational teams in the medical and defense industry, including management of multidisciplinary research and development projects. Before joining DiNovA, Mr. Kirma was the COO and Site Manager of Digma Medical which develops a minimally invasive therapy to treat diabetes. He was also previously Vice President R&D and Site Manager of Endochoice Innovation Center (acquired by Boston Scientific in 2016) and before that, Product Manager at Stryker Endoscopy. Mr. Kirma began his career as a technical team leader at Elbit Systems. He holds a BSc in Electrical Engineering and Physics from the Technion, Haifa.

Mr. Kirma will oversee the incubator's daily operations and take charge of the project management of all portfolio companies. He will help identify more talent or companies to join DiNovA Israel to work on ideas that could explore China market potential by leveraging DiNovA's unique China market resources.

Michael Zhao, CEO of DiNovA said, "Mr. Kirma has high alignment with our mission to bring more innovation to medtech market through China and Israel collaborations. His expertise and network in Israel medtech industry will help attract teams of innovative technologies to work with DiNovA. In the meanwhile, his vast hands-on experiences in operations and project management will also contribute to our long-term success of operating the Israel incubator. "

Commenting on his appointment, Mr. Kirma said, "I am glad to become the Chief Operating Officer of DiNovA Israel. I was impressed by DiNovA's portfolio companies and its continuously expanding global footprint. I believe there is substantial value that Israeli engineering could bring to China healthcare market by working with a strong local partner like DiNovA. I hope to enable deeper communications between the two countries so more practical and valuable medtech ideas could be extracted from the incubator and eventually become life-changing technologies."

About DiNovA Israel Incubator ("DiNovA Israel")

DiNovA Israel was founded in April 2020, to promote cutting-edge medtech technologies, especially digital health innovations, by bridging the Israeli medtech engineering talent with the China market. We hope to bring unique resources from the two countries together to create medical technology innovations that will benefit patients world-wide. For any inquiry including discussing potential ideas or collaborations, please feel free to contact us by writing to: israel@dnamedtech.com

For more information, please visit: https://dinovaisrael.com/

© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.